Press release
2019-02-14
Martin Åmark, CEO of Xbrane Biopharma AB ("Xbrane"), will as of today also be the Head of IR for Xbrane. The reason for this is that Xbrane's current Head of IR and CFO, Susanna Helgesen, will be on parental leave on a part-time basis for a period. During the parental leave, Susanna Helgesen will remain as CFO. The finance team has also been expanded with a Group Financial Controller.
For further information, please contact:
Martin Åmark
CEO/IR
M: +46(0) 763-093 777
E: martin.amark@xbrane.com
Susanna Helgesen
CFO
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com
About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified adviser (corp@avanza.se, +46 (0)8 409 421 20). For more information see www.xbrane.com.
